Syntekabio

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Syntekabio, a genomic big data and AI-driven drug development company, headquartered in Daejeon, South Korea. Area of focus includes AI-guided small molecule drug candidate discovery to accelerate drug discovery process and neoantigen prediction for personalized cancer vaccine development. Syntekabio is currently collaborating with several bio pharma companies and expanding in-house drug development programs. On December 2019, Syntekabio successfully completed IPO for the KOSDAQ market, becoming the world’s first AI drug development company to become public.
Ticker:
226330
Exchange:
KOSDAQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
NEOscan (neoantigen prediction algorithm); STB-C017 (I/O lead)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Medical Science Executive Director
Syntekabio Inc.